our XPRIZE winning HDPCR SARS-CoV-2 Assay.*
Still variant inclusive.
Even more time and cost savings.
*Validation of HDPCR™ SARS-CoV-2 Assay Direct Workflow has not been reviewed by FDA. Review under the EUA program is pending.
The Future of Multiplexing
ChromaCode’s HDPCR™
ChromaCode’s HDPCR™ is moving multiplexing into the future—utilizing digital signal processing, enhanced PCR reagents and cloud-based software. HDPCR™ technology expands multiplexing capabilities up to 4 times – expanding the number of detectable disease targets in a single reaction. HDPCR technology uses traditional qPCR or dPCR instruments without changes to workflow or instrument hardware or software.
4 times the multiplexing capability
4 times the efficiency, 4 times the savings
Expanded multiplexing
4-20 targets in a single reaction; broader coverage for more rapid disease identification
Cost effective
Low-cost chemistry, existing equipment, more results per test, more affordable testing for your lab
Streamlined adoption
HDPCR works on the most common molecular real time and digital PCR systems already installed in labs
Intuitive user interface
Streamlined data analysis and management on ChromaCode Cloud™ software